top of page

MASLD - Metabolic dysfunction–associated steatotic liver disease

August 2026

Join Liz Beverly, PhD and Amber Healy, DO as they discuss the implications of Metabolic dysfunction–associated steatotic liver disease for patients with Type 2 Diabetes.

Several logos and disclaimer that says The SEO QI Hub is funded by the Ohio Department of Medicaid a administered by the Ohio Colleges of Medicine Government Resource Center. The views expressed in this document are solely those of the authors and do not represent the views of the state of Ohio or federal Medicaid programs.

If you have a disability and experience difficulty accessing this content, please contact us at qihub@ohio.edu. 

bottom of page